



## **Agilis Biotherapeutics Supports Workshop on Commercialization of Gene & Cell Therapy Products at the ASGCT Annual Meeting**

**Markus Peters, Ph.D., Agilis Chief Commercial Officer, to moderate panel on gene therapy commercialization**

**Cambridge, MA**, May 9, 2017 -- Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Markus Peters, Ph.D., Agilis Chief Commercial Officer (CCO), will moderate the panel on the Workshop on Gene & Cell Therapy Products held during the 20<sup>th</sup> Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington D.C.

Dr. Peters, who is a member of the organizing committee for the workshop, will chair a session with industry experts showcasing their experience in launching a global gene therapy. The workshop covers key aspects of commercialization of innovative treatments, including regulatory, pricing, reimbursement and launch planning.

“The Commercialization Workshop at ASGCT shows that the biopharmaceutical industry is in the middle of translating the promise of innovative science into the benefit for the patient,” said Dr. Markus Peters. “This is particularly important for the spectrum of rare and serious disorders where few treatment options exist.”

The ASGCT Annual Meeting is the preeminent gene and cell therapy conference in the world bringing together more than 2,400 of the world’s top gene and cell therapy professionals. It features groundbreaking clinical trial results and cutting-edge technology advancements, and is an important venue for building a vibrant community of experts that drive innovation.

Dr. Peters joined Agilis as CCO in April 2017, bringing deep commercial experience in the launch innovative advanced therapeutics for both rare diseases and large-market indications. He is leading Agilis' commercial efforts for the Company's AGIL-AADC gene therapy candidate for the treatment of AADC deficiency, currently in late-stage clinical development.

**About Agilis Biotherapeutics, Inc.**

Agilis is a clinical stage company advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Agilis' gene therapies are engineered to impart sustainable clinical benefits by inducing persistent expression of a therapeutic gene through precise targeting and restoration of lost gene function to achieve long-term efficacy. Agilis' rare disease programs are focused on gene therapy for AADC deficiency, Friedreich's ataxia, and Angelman syndrome, all rare genetic diseases that include neurological deficits and result in physically debilitating conditions.

We invite you to visit our website at [www.agilisbio.com](http://www.agilisbio.com).

**Safe Harbor Statement**

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

**For more information, contact**

**Agilis Biotherapeutics, Inc.**

Dr. Jodi Cook  
Chief Operating Officer  
Email: [jcook@agilisbio.com](mailto:jcook@agilisbio.com)  
Phone: 510-673-7809